Ocugen is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Co. develops, manufactures, and commercializes COVAXIN for the prevention of COVID-19. Co.'s gene therapy candidate, OCU400 is for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3, centrosomal protein 290, rhodopsin, and phosphodiesterase 6B mutation-associated inherited retinal degenerations. Co.'s second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A for the treatment of dry age-related macular degeneration.